Indefinite anticoagulation for unprovoked venous thromboembolism is not cost-effective
1. In this Markov modeling study, indefinite anticoagulation for first unprovoked venous thromboembolism (VTE) cost $16,014 more per person than ...
Tag: anticoagulation
Early versus late post-stroke anticoagulation in patients with atrial fibrillation results in similar outcomes
1. In this randomized controlled trial of patients with atrial fibrillation who had an acute ischemic stroke, early versus late ...
#VisualAbstract: Withholding prophylactic platelet transfusion in thrombocytopenia increases adverse events
1. In this randomized controlled trial, withholding prophylactic platelet transfusion in patients with thrombocytopenia was associated with worse outcomes following ...
Withholding prophylactic platelet transfusion in thrombocytopenia increases adverse events
1. In this randomized controlled trial, withholding prophylactic platelet transfusion in patients with thrombocytopenia was associated with worse outcomes following ...
#VisualAbstract: Early versus later anticoagulation for stroke with atrial fibrillation
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may ...
Apixaban may be safer than other options for long-term anticoagulation
Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation 1. For older adults ...
#VisualAbstract: Addition of argatroban to intravenous alteplase did not improve neurologic outcomes in patients with acute ischemic stroke
Click here to read this study in NEJM
Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women
1. Risk of venous thromboembolism in the antepartum and postpartum period was comparable between the intermediate- and low-dose low-molecular weight ...
Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting
1. The detection rates for newly diagnosed atrial fibrillation were almost five times greater between high-risk patients compared to low-risk ...
Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...